MC
ABMD

Moors & Cabot’s Abiomed Inc ABMD Stock Holding History

Moors & Cabot’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,825
Closed -$325K – 719
2019
Q3 		$325K Buy
1,825
+100
+6% +$21.6K 0.04% 424
2019
Q2 		$450K Sell
1,725
-18
-1% -$4.78K 0.06% 323
2019
Q1 		$497K Buy
1,743
+18
+1% +$5.98K 0.07% 281
2018
Q4 		$561K Sell
1,725
-150
-8% -$52.1K 0.09% 236
2018
Q3 		$842K Buy
1,875
+50
+3% +$19.7K 0.1% 219
2018
Q2 		$746K Buy
1,825
+40
+2% +$14.5K 0.1% 227
2018
Q1 		$519K Buy
+1,785
New +$452K 0.07% 318

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Moors & Cabot's ABMD Position: Q4 2019 in Review

Moors & Cabot sold out of Abiomed Inc (ABMD) in Q4 2019, closing a stake of 1,825 shares — an estimated $325K sold.

Moors & Cabot first reported a position in ABMD in Q1 2018 and held it in 7 quarters. The position peaked at $842K in Q3 2018. 465 funds tracked by Wall St. Rank hold ABMD as of Q4 2019.

  • Moors & Cabot reported no remaining Abiomed Inc position as of Q4 2019 after selling out during the quarter.
  • Moors & Cabot sold 1,825 Abiomed Inc shares in Q4 2019, an estimated $325K.
  • Moors & Cabot first reported a position in Abiomed Inc in Q1 2018 and held it in 7 quarters.
  • Moors & Cabot's Abiomed Inc position peaked at $842K in Q3 2018.
  • 465 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2019.

Based on Moors & Cabot's 13F filing for Q4 2019, filed 28 Jan 2020.